GH Cochin Broca Hôtel-Dieu
Welcome,         Profile    Billing    Logout  
 14 Trials 
5 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ALEXANDRE, Jérôme
DOMENICA, NCT05201547 / 2021-002124-21: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Recruiting
3
260
Europe, Canada, Japan, RoW
Carboplatin-Paclitaxel, Dostarlimab
ARCAGY/ GINECO GROUP, GlaxoSmithKline
Endometrial Cancer
04/26
10/29
TEDOVA, NCT04713514 / 2020-004364-25: OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Active, not recruiting
2
180
Europe
OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475
ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC
Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer
12/25
12/25
KURTZ, Jean-Emmanuel
ATALANTE, NCT02891824 / 2015-005471-24: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

Checkmark Presentation of data from ATALANTE trial for 3L ovarian cancer at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from ATALANTE trial for 3L ovarian cancer at ESMO 2022
Completed
3
614
Europe, RoW
atezolizumab + avastin + platinum-based chemotherapy, Tecentriq, placebo + avastin + platinum-based chemotherapy
ARCAGY/ GINECO GROUP, Hoffmann-La Roche
Ovarian Cancer
10/21
02/24
CIRSARC, NCT03805022 / 2018-000186-36: Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas

Recruiting
3
351
Europe
Doxorubicin, Ifosfamide or dacarbazine, At the discretion of the investigator
Institut Bergonié, Novartis, Chugai Pharma France
Non-metastatic Soft-tissue Sarcoma, Resectable
02/25
02/25
L-UteCIN, NCT06524583: Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Recruiting
2
198
Europe
Doxorubicin, Trabectedin, Yondelis
UNICANCER, PharmaMar, Ligue contre le cancer, France, National Research Agency, France, University Hospital, Marseille, Institut Claudius Regaud, Institut Bergonié, Oncopole
Leiomyosarcoma Uterus
12/29
12/30
COCK, Laure DE
No trials found
DINXH-XUAN, Anh Tuan
No trials found
TRA, Thi-Tuyet-Suong
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ALEXANDRE, Jérôme
DOMENICA, NCT05201547 / 2021-002124-21: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

Recruiting
3
260
Europe, Canada, Japan, RoW
Carboplatin-Paclitaxel, Dostarlimab
ARCAGY/ GINECO GROUP, GlaxoSmithKline
Endometrial Cancer
04/26
10/29
TEDOVA, NCT04713514 / 2020-004364-25: OSE2101 Alone or in Combination With Pembrolizumab vs BSC in Patient With Platinum-sensitive Recurrent OC

Active, not recruiting
2
180
Europe
OSE2101, TEDOPI®, Pembrolizumab 25 MG/ML [Keytruda], KEYTRUDA®, MK-3475
ARCAGY/ GINECO GROUP, OSE Immunotherapeutics, Merck Sharp & Dohme LLC
Platinum-sensitive Ovarian Cancer, Relapsed Ovarian Cancer
12/25
12/25
KURTZ, Jean-Emmanuel
ATALANTE, NCT02891824 / 2015-005471-24: Atezolizumab vs Placebo Phase III Study in Late Relapse Ovarian Cancer Treated With Chemotherapy+Bevacizumab

Checkmark Presentation of data from ATALANTE trial for 3L ovarian cancer at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from ATALANTE trial for 3L ovarian cancer at ESMO 2022
Completed
3
614
Europe, RoW
atezolizumab + avastin + platinum-based chemotherapy, Tecentriq, placebo + avastin + platinum-based chemotherapy
ARCAGY/ GINECO GROUP, Hoffmann-La Roche
Ovarian Cancer
10/21
02/24
CIRSARC, NCT03805022 / 2018-000186-36: Benefit of Intensified Peri-operative Chemotherapy Within High-risk CINSARC Patients With Resectable Soft-tissue Sarcomas

Recruiting
3
351
Europe
Doxorubicin, Ifosfamide or dacarbazine, At the discretion of the investigator
Institut Bergonié, Novartis, Chugai Pharma France
Non-metastatic Soft-tissue Sarcoma, Resectable
02/25
02/25
L-UteCIN, NCT06524583: Interest of Post-operative Chemotherapy in Patients With Localised Uterine Leiomyosarcoma Suspected of Having a High Risk of Recurrence Based on a Biological Test Performed on the Tumour

Recruiting
2
198
Europe
Doxorubicin, Trabectedin, Yondelis
UNICANCER, PharmaMar, Ligue contre le cancer, France, National Research Agency, France, University Hospital, Marseille, Institut Claudius Regaud, Institut Bergonié, Oncopole
Leiomyosarcoma Uterus
12/29
12/30
COCK, Laure DE
No trials found
DINXH-XUAN, Anh Tuan
No trials found
TRA, Thi-Tuyet-Suong
No trials found

Download Options